Feed TIL
TI

Instil Bio, Inc.

TIL · NASDAQ

$7.09 -0.28% (-$0.02)
1M -6.46%
Market Cap $48.9M
P/E Ratio -
Div. Yield -
ROE 26.78%

Bulios Fair Price

$8.53

20.3% upside

Current Price

$7.09

Undervalued Fair Value Overvalued

According to Bulios Fair Price, TIL is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Weak
3/9
Valuation
100 /100
Cheap
P/B 0.46x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining
Book val. growth 32.09%
EPS growth N/A
Rev. growth N/A
Profitability
-
N/A
Gross margin N/A
Net margin N/A
Op. margin N/A
Quality
0 /100
Poor
ROIC 18.61%
ROE 26.78%
ROA 15.32%
Debt
69 /100
Low
Debt/Equity 0.03x
Current ratio 21.67x
Int. coverage -5.44x
Stability
35 /100
Moderate
Beta 1.92x
EPS volatility 23.25%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about TIL
Online

About the company

Instil Bio, Inc. is a U.S.-based biotechnology company headquartered in Massachusetts, specializing in the development and production of advanced immunotherapies for cancer treatment. The company utilizes cutting-edge T-cell modification technologies to enhance the efficacy of immunotherapy and improve treatment outcomes for patients with various types of cancer. Instil Bio collaborates with academic and industrial partners and focuses on developing innovative and personalized approaches in the field of oncology immunotherapy.

Sector

Healthcare

Industry

Biotechnology

CEO

Bronson Crouch

Employees

17

Headquarters

Dallas

Upcoming events

16 NOV

Earnings

Upcoming earnings report

57d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.